1. Field of the Invention
In some embodiments this invention relates to implantable medical devices, their manufacture, and methods of use. Some embodiments are directed to delivery systems, such as catheter systems of all types, which are utilized in the delivery of such devices.
2. Description of the Related Art
A stent is a medical device introduced to a body lumen and is well known in the art. Typically, a stent is implanted in a blood vessel at the site of a stenosis or aneurysm endoluminally, i.e. by so-called “minimally invasive techniques” in which the stent in a radially reduced configuration, optionally restrained in a radially compressed configuration by a sheath and/or catheter, is delivered by a stent delivery system or “introducer” to the site where it is required. The introducer may enter the body from an access location outside the body, such as through the patient's skin, or by a “cut down” technique in which the entry blood vessel is exposed by minor surgical means.
Stents, grafts, stent-grafts, vena cava filters, expandable frameworks, and similar implantable medical devices, collectively referred to hereinafter as stents, are radially expandable endoprostheses which are typically intravascular implants capable of being implanted transluminally and enlarged radially after being introduced percutaneously. Stents may be implanted in a variety of body lumens or vessels such as within the vascular system, urinary tracts, bile ducts, fallopian tubes, coronary vessels, secondary vessels, etc. Stents may be used to reinforce body vessels and to prevent restenosis following angioplasty in the vascular system. They may be self-expanding, expanded by an internal radial force, such as when mounted on a balloon, or a combination of self-expanding and balloon expandable (hybrid expandable).
Stents may be created by methods including cutting or etching a design from a tubular stock, from a flat sheet which is cut or etched and which is subsequently rolled or from one or more interwoven wires or braids.
Within the vasculature, it is not uncommon for stenoses to form at a vessel bifurcation. A bifurcation is an area of the vasculature or other portion of the body where a first (or parent) vessel is bifurcated into two or more branch vessels. Where a stenotic lesion or lesions form at such a bifurcation, the lesion(s) can affect only one of the vessels (i.e., either of the branch vessels or the parent vessel) two of the vessels, or all three vessels. Many prior art stents however are not wholly satisfactory for use where the site of desired application of the stent is juxtaposed or extends across a bifurcation in an artery or vein such, for example, as the bifurcation in the mammalian aortic artery into the common iliac arteries.
Stents for use in bifurcated regions are generally known. When treating a bifurcated vessel, it may desirable to use a stent having a side branch opening configured to provide fluid communication between the primary vessel and a secondary or branch vessel of the bifurcation. A secondary or branch stent may be received within and/or be positioned adjacent to the side branch opening of the primary stent.
A side opening in some stents may further include a structural component, which when deployed, extends from the primary stent and into the branch vessel. In some instances a side branch structure (e.g. limb, arm, branch, etc.) exhibits expansion characteristics that are different from other portions of the primary stent. In some instances, it may be difficult to initiate an outward expansion of the side branch. In some instances, strut members of the stent in areas around the side opening must be designed to help compensate for the expansion characteristics of the side opening. Therefore, strut members adjacent to a side opening may be designed differently than strut members of the main body portion of the stent, and may experience higher stress levels, greater amounts of strain and provide less scaffolding support.
There remains a need for a stent having a side branch which exhibits superior expansion characteristics. It would further be desirable to provide a stent wherein strut design adjacent to a side opening provides a high level of scaffolding support and more closely matches the design of other portions of the stent.
The art referred to and/or described above is not intended to constitute an admission that any patent, publication or other information referred to herein is “prior art” with respect to this invention. In addition, this section should not be construed to mean that a search has been made or that no other pertinent information as defined in 37 C.F.R. §1.56(a) exists.
All US patents and applications and all other published documents mentioned anywhere in this application are incorporated herein by reference in their entirety.
Without limiting the scope of the invention a brief summary of some of the claimed embodiments of the invention is set forth below. Additional details of the summarized embodiments of the invention and/or additional embodiments of the invention may be found in the Detailed Description of the Invention below.
A brief abstract of the technical disclosure in the specification is provided as well only for the purposes of complying with 37 C.F.R. 1.72. The abstract is not intended to be used for interpreting the scope of the claims.
In at least one embodiment, a stent may have a longitudinal axis and may comprise a side branch cell. The side branch cell may comprise a plurality of petals including a first petal, and each petal may comprise a plurality of substantially straight struts and at least one turn. Each petal may have a central axis, and the central axis of the first petal may extend in a direction nonparallel to the stent longitudinal axis. At least two of said substantially straight struts of the first petal may extend substantially parallel to said stent longitudinal axis.
In another embodiment, a stent may comprise a body having a longitudinal axis and may be expandable from an unexpanded state to an expanded state. The stent body may define a plurality of interconnected strut members. A plurality of said interconnected strut members may comprise a plurality of petals, and the plurality of petals may define a side branch opening. Each petal may have a longitudinal axis and may further comprise at least one appendage. Each appendage may have a longitudinal axis and may comprise a first strut member, a turn and a second strut member. When the stent is in the unexpanded state, the longitudinal axis of each appendage may be substantially parallel to the longitudinal axis of the body.
These and other embodiments which characterize the invention are pointed out with particularity in the claims annexed hereto and forming a part hereof. However, for a better understanding of the invention, its advantages and objectives obtained by its use, reference should be made to the drawings which form a further part hereof and the accompanying descriptive matter, in which there are illustrated and described various embodiments of the invention.
A detailed description of the invention is hereafter described with specific reference being made to the drawings.
While this invention may be embodied in many different forms, there are described in detail herein specific preferred embodiments of the invention. This description is an exemplification of the principles of the invention and is not intended to limit the invention to the particular embodiments illustrated.
For the purposes of this disclosure, like reference numerals in the figures shall refer to like features unless otherwise indicated. Use of the term “parallel” is intended to describe an orientation in which two elements may be exactly parallel or substantially parallel to one another.
The stent patterns depicted herein are generally shown and described as flat patterns. A person of ordinary skill in the art will understand that a cylindrical stent may be manufactured according to the design of the flat patterns disclosed.
Some examples of stents having a side opening and methods of deploying such stents are disclosed in U.S. Pat. Nos. 5,596,020 and 6,835,203, the entire disclosures of which are hereby incorporated herein in their entireties.
The entire disclosures of U.S. Pat. Nos. 5,922,021, 6,123,721, 6,334,870, 6,478,816, 6,348,065 and 6,325,826 are hereby incorporated herein by reference in their entireties.
A side branch cell 30 may comprise a continuous strut member 32, or in some embodiments a plurality of strut members, which may extend in serpentine fashion about the center 34 of the side branch cell 30. The side branch cell 30 desirably defines a plurality of side branch petals 40 which may have any suitable shape and may each be oriented in any suitable direction. A side branch cell 30 may have any suitable number of petals 40 and in some embodiments may have anywhere from six to ten petals 40. In some embodiments, the pattern of the continuous strut member(s) 32 may define the plurality of side branch petals 40.
Each petal 40 may have an approximate longitudinal axis 42. In some embodiments, a petal 40 may have a longitudinal axis 42 which is oriented to extend substantially radially outwardly from the center 34 of the side branch cell 30. A longitudinal axis 42 may pass through the centroid of the stent elements which comprise the petal 40.
Each petal 40 may comprise a plurality of struts 36 and at least one turn 38. A strut 36 may be straight along its length, and may be oriented in any suitable direction. A turn 38 may be oriented in any suitable direction. In some embodiments, a turn 38 may comprise a proximal turn 38p oriented with a peak facing the proximal end 11 of the stent 10, or a distal turn 38d oriented with a peak facing the distal end 13 of the stent 10. Petals 40 which are adjacent to one another about the side branch cell 30 may be connected to one another by a connecting portion 44. In various locations, a connecting portion 44 may comprise a turn 38, a strut 36, or any combination of one or more turns 38 and one or more struts 36.
A petal 40 may include struts 36 that are oriented substantially parallel to the longitudinal axis 18 of the stent 10, and/or may include struts 36 that are oriented substantially parallel to the longitudinal axis 42 of the petal 40. In some embodiments, one or more struts 36 may be oriented at a range from 30° to 60° with respect to the longitudinal axis 18 of the stent 10. In some embodiments, one or more struts 36 may be oriented at approximately 45° with respect to the longitudinal axis 18 of the stent 10. In some embodiments, a petal may include a plurality of struts 36 that are oriented substantially parallel to the longitudinal axis 18 of the stent 10. This may be true even though the longitudinal axis 42 of the petal 40 may be oriented at an angle with respect to the longitudinal axis 18 of the stent 10. In some embodiments, a majority of the struts 36 or all of the struts 36 in a petal 40 may be oriented substantially parallel to the longitudinal axis 18 of the stent 10.
Each petal 40 may further comprise one or more appendages 70. An appendage 70 may comprise a first strut 36a and a second strut 36b connected by a turn 38. In some embodiments, an appendage 70 may include a proximal turn 38p, or may include a distal turn 38d. An appendage 70 may have an approximate longitudinal axis 72, and the approximate longitudinal axis 72 may be substantially parallel to the longitudinal axis 18 of the stent 10.
Each petal 40 may further include a circumferential length component 48, or a distance between opposed circumferential extremities 45, 47 of a petal 40 as measured in a direction about the circumference of the stent. As with the proximal most and distal most points 41, 43 of a petal 40, the locations of points which comprise the opposed circumferential extremities 45, 47 for a given petal 40 may change with stent crimping and/or stent expansion. The circumferential length component 48 of a petal 40 may be perpendicular to the longitudinal length component 46 of the petal 40.
Similar to the circumferential length component 48 and longitudinal length component 46 of a petal 40, a side branch cell 30 may include a longitudinal length component 26, or a distance between proximal most and distal most points of the side branch cell 30 as measured parallel to the stent longitudinal axis 18. A side branch cell 30 may also include a circumferential length component 28, or a distance between opposed extremities of the side branch cell 30 as measured in a direction about the circumference of the stent. The locations of a proximal most point, a distal most point, and the opposed circumferential extremities may change as a side branch cell 30 may change in size and shape with stent crimping and/or stent expansion. The longitudinal length component 26 of the side branch cell 30 may be perpendicular to the circumferential length component 28.
The geometric design of various embodiments of a side branch cell 30, including the design of the individual petals 40 within a side branch cell 30, desirably allows a stent 10 to expand more similarly to a standard stent not having a side branch cell 30. Desirably, upon expansion, the circumferential length component 28, 48 of a petal 40 or a side branch cell 30 may experience an increase that is proportionally larger than any related increase in the longitudinal length component 26, 46 of the respective petal 40 or side branch cell 30. In some embodiments, a longitudinal length component 26, 46 may remain the same or even reduce as the stent 10 expands. The geometric design of the petals 40, and particularly the petals 40 which have an approximate longitudinal axis 42 that is nonparallel to the stent longitudinal axis 18 and a plurality of struts 36 which are oriented substantially parallel to the stent longitudinal axis 18, allows for a relatively large increase in the circumferential length component 28, 48 as compared to any change (i.e. increase or decrease) in the longitudinal length component 26, 46 of the petal 40 or side branch cell 30 during stent expansion.
As a stent expands, the petals 40 may change shape, and the orientation of struts 36 and turns 38 may also change. Struts 36 which are substantially parallel to the stent longitudinal axis 18 in an unexpanded state may reorient on expansion and be nonparallel to the stent longitudinal axis 18 when the stent is expanded.
Appendages 70 may also change shape as the stent expands. In some embodiments, although an appendage 70 may change shape, the approximate longitudinal axis 72 of the appendage 70 may remain substantially parallel to the stent longitudinal axis 18 after expansion.
An appendage 70 may have a longitudinal axis 72 which is a predetermined distance away from a longitudinal axis 31 of the side branch cell 30, as measured in a stent circumferential direction.
As the stent expands, each appendage longitudinal axis 72 may displace away from the side branch cell longitudinal axis 31. The greater the distance 74 between the appendage longitudinal axis 72 and the side branch cell longitudinal axis 31, the greater the increase in the distance 74 may be. For example, during expansion, appendage longitudinal axis 72a may displace away from the side branch cell longitudinal axis 31. Appendage longitudinal axis 72b may also displace away from the side branch cell longitudinal axis 31. The amount of displacement of appendage longitudinal axis 72b may be greater than the amount of displacement of appendage longitudinal axis 72a. Similarly, appendage longitudinal axis 72c may also displace away from the side branch cell longitudinal axis 31, and the amount of displacement of appendage longitudinal axis 72c may be greater than the amount of displacement of appendage longitudinal axis 72b.
Referring again to
A stent 10 may include side branch connectors 56 which may connect between the side branch cell 30 and other portions of the stent 10. A side branch connector 56 may extend from any portion of a side branch cell 30, such as a petal 40 or connecting portion 44, and connect to any other portion of the stent 10, such as a serpentine band 12 or a partial serpentine band 60.
In some embodiments, a side branch connector 56 may include straight portions, peaks, valleys or other undulations. In some embodiments, a side branch connector 56 may comprise a flexible connector which may support an ostium when deployed in a vessel.
Desirably, the design of a side branch cell 30, and particularly the design of petals 40 having a plurality of struts 36 oriented substantially parallel to the stent longitudinal axis 10, may allow for more struts 14 and turns 16 in a partial serpentine band 60 than prior art designs. The design of a side branch cell 30 may also allow the design of the partial serpentine band(s) 60 to be consistent with the design of the standard serpentine bands 12. This allows the stent to provide more scaffolding support to vessel locations adjacent to the petal 40 region, particularly around juncture points between a main branch vessel and a side branch vessel, such as the carina and vessel areas contralateral to the carina.
The design of a side branch cell 30 also allows for the circumferential length component 28 of the side branch cell 30 to be further reduced as the stent 10 is further crimped to an unexpanded configuration which is more reduced than shown in
All of the descriptions of a stent 10 and side branch cell 30 with respect to
Each petal 40 may further comprise a plurality of appendages 70. A single petal 40 may include appendages 70 that are oriented in different or opposite directions. A single petal 40 may include at least one appendage having a proximal turn 38p, and at least one other appendage 70 having a distal turn 38d.
Each petal 80 may have a longitudinal axis 82. In at least a nominal state, petals 80 which are adjacent to one another along the length of the stent may have longitudinal axes 82 which share a common line. Petals 80 which are adjacent to one another about the circumference of the stent may have longitudinal axes 82 which are substantially parallel to one another. Petals 80 may have a longitudinal axis 82 which is substantially parallel to the longitudinal axis of the stent.
The inventive stents may be made from any suitable biocompatible materials including one or more polymers, one or more metals or combinations of polymer(s) and metal(s). Examples of suitable materials include biodegradable materials that are also biocompatible. By biodegradable is meant that a material will undergo breakdown or decomposition into harmless compounds as part of a normal biological process. Suitable biodegradable materials include polylactic acid, polyglycolic acid (PGA), collagen or other connective proteins or natural materials, polycaprolactone, hylauric acid, adhesive proteins, co-polymers of these materials as well as composites and combinations thereof and combinations of other biodegradable polymers. Other polymers that may be used include polyester and polycarbonate copolymers. Examples of suitable metals include, but are not limited to, stainless steel, titanium, tantalum, platinum, tungsten, gold and alloys of any of the above-mentioned metals. Examples of suitable alloys include platinum-iridium alloys, cobalt-chromium alloys including Elgiloy and Phynox, MP35N alloy and nickel-titanium alloys, for example, Nitinol.
The inventive stents may be made of shape memory materials such as superelastic Nitinol or spring steel, or may be made of materials which are plastically deformable. In the case of shape memory materials, the stent may be provided with a memorized shape and then deformed to a reduced diameter shape. The stent may restore itself to its memorized shape upon being heated to a transition temperature and having any restraints removed therefrom.
The inventive stents may be created by methods including cutting or etching a design from a tubular stock, from a flat sheet which is cut or etched and which is subsequently rolled or from one or more interwoven wires or braids. Any other suitable technique which is known in the art or which is subsequently developed may also be used to manufacture the inventive stents disclosed herein.
In some embodiments the stent, the delivery system or other portion of the assembly may include one or more areas, bands, coatings, members, etc. that is (are) detectable by imaging modalities such as X-Ray, MRI, ultrasound, etc. In some embodiments at least a portion of the stent and/or adjacent assembly is at least partially radiopaque.
In some embodiments, at least a portion of the stent is configured to include one or more mechanisms for the delivery of a therapeutic agent. Often the agent will be in the form of a coating or other layer (or layers) of material placed on a surface region of the stent, which is adapted to be released at the site of stent implantation or areas adjacent thereto.
A therapeutic agent may be a drug or other pharmaceutical product such as non-genetic agents, genetic agents, cellular material, etc. Some examples of suitable non-genetic therapeutic agents include but are not limited to: anti-thrombogenic agents such as heparin, heparin derivatives, vascular cell growth promoters, growth factor inhibitors, Paclitaxel, etc. Where an agent includes a genetic therapeutic agent, such a genetic agent may include but is not limited to: DNA, RNA and their respective derivatives and/or components; hedgehog proteins, etc. Where a therapeutic agent includes cellular material, the cellular material may include but is not limited to: cells of human origin and/or non-human origin as well as their respective components and/or derivatives thereof. Where the therapeutic agent includes a polymer agent, the polymer agent may be a polystyrene-polyisobutylene-polystyrene triblock copolymer (SIBS), polyethylene oxide, silicone rubber and/or any other suitable substrate.
The above disclosure is intended to be illustrative and not exhaustive. This description will suggest many variations and alternatives to one of ordinary skill in this field of art. All these alternatives and variations are intended to be included within the scope of the claims where the term “comprising” means “including, but not limited to”. Those familiar with the art may recognize other equivalents to the specific embodiments described herein which equivalents are also intended to be encompassed by the claims.
Further, the particular features presented in the dependent claims can be combined with each other in other manners within the scope of the invention such that the invention should be recognized as also specifically directed to other embodiments having any other possible combination of the features of the dependent claims. For instance, for purposes of claim publication, any dependent claim which follows should be taken as alternatively written in a multiple dependent form from all prior claims which possess all antecedents referenced in such dependent claim if such multiple dependent format is an accepted format within the jurisdiction (e.g. each claim depending directly from claim 1 should be alternatively taken as depending from all previous claims). In jurisdictions where multiple dependent claim formats are restricted, the following dependent claims should each be also taken as alternatively written in each singly dependent claim format which creates a dependency from a prior antecedent-possessing claim other than the specific claim listed in such dependent claim below.
This completes the description of the preferred and alternate embodiments of the invention. Those skilled in the art may recognize other equivalents to the specific embodiment described herein which equivalents are intended to be encompassed by the claims attached hereto.
Number | Name | Date | Kind |
---|---|---|---|
4309994 | Grunwald | Jan 1982 | A |
4769005 | Ginsburg et al. | Sep 1988 | A |
4774949 | Fogarty | Oct 1988 | A |
4896670 | Crittenden | Jan 1990 | A |
4905667 | Foerster et al. | Mar 1990 | A |
4994071 | MacGregor | Feb 1991 | A |
5342387 | Summers | Aug 1994 | A |
5387235 | Chuter | Feb 1995 | A |
5456712 | Maginot | Oct 1995 | A |
5476471 | Shifrin et al. | Dec 1995 | A |
5487730 | Marcadis et al. | Jan 1996 | A |
5591228 | Edoga | Jan 1997 | A |
5596020 | Morris | Jan 1997 | A |
5607444 | Lam | Mar 1997 | A |
5609605 | Marshall et al. | Mar 1997 | A |
5609627 | Goicoechea et al. | Mar 1997 | A |
5613980 | Chauhan | Mar 1997 | A |
5617878 | Taheri | Apr 1997 | A |
5632762 | Myler | May 1997 | A |
5632763 | Glastra | May 1997 | A |
5632772 | Alcime et al. | May 1997 | A |
5636641 | Fariabi | Jun 1997 | A |
5669924 | Shaknovich | Sep 1997 | A |
5669932 | Fischell et al. | Sep 1997 | A |
5676697 | McDonald | Oct 1997 | A |
5683450 | Goicoechea et al. | Nov 1997 | A |
5697971 | Fischell et al. | Dec 1997 | A |
5707348 | Krogh | Jan 1998 | A |
5709713 | Evans et al. | Jan 1998 | A |
5720735 | Dorros | Feb 1998 | A |
5749825 | Fischell et al. | May 1998 | A |
5749890 | Shaknovich | May 1998 | A |
5755734 | Richter et al. | May 1998 | A |
5755735 | Richter et al. | May 1998 | A |
5755771 | Penn et al. | May 1998 | A |
5755773 | Evans et al. | May 1998 | A |
5755778 | Kleshinski | May 1998 | A |
5782906 | Marshall et al. | Jul 1998 | A |
5824036 | Lauterjung | Oct 1998 | A |
5824040 | Cox et al. | Oct 1998 | A |
5827320 | Richter et al. | Oct 1998 | A |
5851464 | Davila et al. | Dec 1998 | A |
5868777 | Lam | Feb 1999 | A |
5893887 | Jayaraman | Apr 1999 | A |
5922021 | Jang | Jul 1999 | A |
5961548 | Shmulewitz | Oct 1999 | A |
5972017 | Berg et al. | Oct 1999 | A |
6013054 | Jiun Yan | Jan 2000 | A |
6013091 | Ley et al. | Jan 2000 | A |
6017324 | Tu et al. | Jan 2000 | A |
6017363 | Hojeibane | Jan 2000 | A |
6030414 | Taheri | Feb 2000 | A |
6033434 | Borghi | Mar 2000 | A |
6033435 | Penn et al. | Mar 2000 | A |
6056775 | Borghi et al. | May 2000 | A |
6059824 | Taheri | May 2000 | A |
6068655 | Seguin et al. | May 2000 | A |
6086611 | Duffy et al. | Jul 2000 | A |
6093203 | Uflacker | Jul 2000 | A |
6096073 | Webster et al. | Aug 2000 | A |
6099497 | Adams et al. | Aug 2000 | A |
6113579 | Eidenschink et al. | Sep 2000 | A |
6117117 | Mauch | Sep 2000 | A |
6117156 | Richter et al. | Sep 2000 | A |
6123721 | Jang | Sep 2000 | A |
6129738 | Lashinski et al. | Oct 2000 | A |
6142973 | Carleton et al. | Nov 2000 | A |
6143002 | Vietmeier | Nov 2000 | A |
6159238 | Killion et al. | Dec 2000 | A |
6165195 | Wilson et al. | Dec 2000 | A |
6168621 | Vrba | Jan 2001 | B1 |
6183509 | Dibie | Feb 2001 | B1 |
6203568 | Lombardi et al. | Mar 2001 | B1 |
6210380 | Mauch | Apr 2001 | B1 |
6210429 | Vardi et al. | Apr 2001 | B1 |
6210433 | Larre | Apr 2001 | B1 |
6231599 | Ley | May 2001 | B1 |
6254593 | Wilson | Jul 2001 | B1 |
6258115 | Dubrul | Jul 2001 | B1 |
6258116 | Hojeibane | Jul 2001 | B1 |
6261305 | Marotta et al. | Jul 2001 | B1 |
6261316 | Shaolian et al. | Jul 2001 | B1 |
6264662 | Lauterjung | Jul 2001 | B1 |
6264686 | Rieu et al. | Jul 2001 | B1 |
6290673 | Shanley | Sep 2001 | B1 |
6293968 | Taheri | Sep 2001 | B1 |
6325826 | Vardi et al. | Dec 2001 | B1 |
6334864 | Amplatz et al. | Jan 2002 | B1 |
6334870 | Ehr | Jan 2002 | B1 |
6346089 | Dibie | Feb 2002 | B1 |
6348065 | Brown | Feb 2002 | B1 |
6355060 | Lenker et al. | Mar 2002 | B1 |
6361544 | Wilson et al. | Mar 2002 | B1 |
6361555 | Wilson | Mar 2002 | B1 |
6383213 | Wilson et al. | May 2002 | B2 |
6395018 | Castaneda | May 2002 | B1 |
6436104 | Hojeibane | Aug 2002 | B2 |
6436134 | Richter et al. | Aug 2002 | B2 |
6478816 | Kveen et al. | Nov 2002 | B1 |
6508836 | Wilson et al. | Jan 2003 | B2 |
6517558 | Gittings et al. | Feb 2003 | B2 |
6520988 | Colombo et al. | Feb 2003 | B1 |
6540779 | Richter et al. | Apr 2003 | B2 |
6579309 | Loos et al. | Jun 2003 | B1 |
6579312 | Wilson et al. | Jun 2003 | B2 |
6582394 | Reiss et al. | Jun 2003 | B1 |
6596020 | Vardi et al. | Jul 2003 | B2 |
6599316 | Vardi et al. | Jul 2003 | B2 |
6645242 | Quinn | Nov 2003 | B1 |
6689156 | Davidson et al. | Feb 2004 | B1 |
6692483 | Vardi et al. | Feb 2004 | B2 |
6695877 | Brucker et al. | Feb 2004 | B2 |
6706062 | Vardi et al. | Mar 2004 | B2 |
6749628 | Callol et al. | Jun 2004 | B1 |
6776793 | Brown et al. | Aug 2004 | B2 |
6811566 | Penn et al. | Nov 2004 | B1 |
6835203 | Vardi et al. | Dec 2004 | B1 |
6858038 | Heuser | Feb 2005 | B2 |
6884258 | Vardi et al. | Apr 2005 | B2 |
6896699 | Wilson et al. | May 2005 | B2 |
6932837 | Amplatz et al. | Aug 2005 | B2 |
6955687 | Richter et al. | Oct 2005 | B2 |
6955688 | Wilson et al. | Oct 2005 | B2 |
6962602 | Vardi et al. | Nov 2005 | B2 |
7018400 | Lashinski et al. | Mar 2006 | B2 |
7056323 | Mareiro et al. | Jun 2006 | B2 |
7060091 | Killion et al. | Jun 2006 | B2 |
7220275 | Davidson et al. | May 2007 | B2 |
20010003161 | Vardi et al. | Jun 2001 | A1 |
20010004706 | Hojeibane | Jun 2001 | A1 |
20010004707 | Dereurne et al. | Jun 2001 | A1 |
20010012927 | Mauch | Aug 2001 | A1 |
20010016766 | Vardi et al. | Aug 2001 | A1 |
20010016767 | Wilson et al. | Aug 2001 | A1 |
20010016768 | Wilson et al. | Aug 2001 | A1 |
20010025195 | Shaolian et al. | Sep 2001 | A1 |
20010027291 | Shanley | Oct 2001 | A1 |
20010027338 | Greenberg | Oct 2001 | A1 |
20010029396 | Wilson et al. | Oct 2001 | A1 |
20010037116 | Wilson et al. | Nov 2001 | A1 |
20010037138 | Wilson et al. | Nov 2001 | A1 |
20010039448 | Dibie | Nov 2001 | A1 |
20010049552 | Richter et al. | Dec 2001 | A1 |
20010056297 | Hojeibane | Dec 2001 | A1 |
20020013618 | Marotta et al. | Jan 2002 | A1 |
20020013619 | Shanley | Jan 2002 | A1 |
20020022874 | Wilson | Feb 2002 | A1 |
20020026232 | Marotta et al. | Feb 2002 | A1 |
20020035392 | Wilson | Mar 2002 | A1 |
20020042650 | Vardi et al. | Apr 2002 | A1 |
20020052648 | McGuckin, Jr. et al. | May 2002 | A1 |
20020072790 | McGuckin, Jr. et al. | Jun 2002 | A1 |
20020111675 | Wilson | Aug 2002 | A1 |
20020156516 | Vardi et al. | Oct 2002 | A1 |
20020156517 | Perouse | Oct 2002 | A1 |
20020165604 | Shanley | Nov 2002 | A1 |
20020173835 | Bourang et al. | Nov 2002 | A1 |
20020173840 | Brucker et al. | Nov 2002 | A1 |
20020183763 | Callol et al. | Dec 2002 | A1 |
20020193872 | Trout, III et al. | Dec 2002 | A1 |
20020193873 | Brucker et al. | Dec 2002 | A1 |
20030009209 | Hojeibane | Jan 2003 | A1 |
20030028233 | Vardi et al. | Feb 2003 | A1 |
20030050688 | Fischell et al. | Mar 2003 | A1 |
20030055378 | Wang et al. | Mar 2003 | A1 |
20030055483 | Gumm | Mar 2003 | A1 |
20030074047 | Richter | Apr 2003 | A1 |
20030093109 | Mauch | May 2003 | A1 |
20030097169 | Brucker | May 2003 | A1 |
20030114912 | Sequin et al. | Jun 2003 | A1 |
20030125791 | Sequin et al. | Jul 2003 | A1 |
20030125802 | Callol et al. | Jul 2003 | A1 |
20030135259 | Simso | Jul 2003 | A1 |
20030181923 | Vardi | Sep 2003 | A1 |
20030195606 | Davidson et al. | Oct 2003 | A1 |
20040006381 | Sequin et al. | Jan 2004 | A1 |
20040015227 | Vardi et al. | Jan 2004 | A1 |
20040044396 | Clerc et al. | Mar 2004 | A1 |
20040059406 | Cully et al. | Mar 2004 | A1 |
20040088007 | Eidenschink | May 2004 | A1 |
20040117003 | Ouriel et al. | Jun 2004 | A1 |
20040133268 | Davidson et al. | Jul 2004 | A1 |
20040138732 | Suhr et al. | Jul 2004 | A1 |
20040138737 | Davidson et al. | Jul 2004 | A1 |
20040148006 | Davidson et al. | Jul 2004 | A1 |
20040172121 | Eidenschink et al. | Sep 2004 | A1 |
20040186560 | Alt | Sep 2004 | A1 |
20040225345 | Fischell et al. | Nov 2004 | A1 |
20040267352 | Davidson et al. | Dec 2004 | A1 |
20050004656 | Das | Jan 2005 | A1 |
20050010278 | Vardi et al. | Jan 2005 | A1 |
20050015108 | Williams et al. | Jan 2005 | A1 |
20050015135 | Shanley | Jan 2005 | A1 |
20050060027 | Khenansho et al. | Mar 2005 | A1 |
20050096726 | Sequin et al. | May 2005 | A1 |
20050102021 | Osborne | May 2005 | A1 |
20050102023 | Yadin et al. | May 2005 | A1 |
20050119731 | Brucker et al. | Jun 2005 | A1 |
20050125076 | Ginn | Jun 2005 | A1 |
20050131526 | Wong | Jun 2005 | A1 |
20050149161 | Eidenschink et al. | Jul 2005 | A1 |
20050154442 | Eidenschink et al. | Jul 2005 | A1 |
20050154444 | Quadri | Jul 2005 | A1 |
20050183259 | Eidenschink et al. | Aug 2005 | A1 |
20050209673 | Shaked | Sep 2005 | A1 |
20050228483 | Kaplan et al. | Oct 2005 | A1 |
20060036315 | Yadin et al. | Feb 2006 | A1 |
20060041303 | Israel | Feb 2006 | A1 |
20060079956 | Eigler et al. | Apr 2006 | A1 |
20060173528 | Feld et al. | Aug 2006 | A1 |
20070073376 | Krolik et al. | Mar 2007 | A1 |
Number | Date | Country |
---|---|---|
2220864 | Jul 1999 | CA |
9014845 | Feb 1991 | DE |
29701758 | Mar 1997 | DE |
29701883 | May 1997 | DE |
0479730 | Oct 1991 | EP |
0751752 | Jan 1997 | EP |
0783873 | Jul 1997 | EP |
0804907 | Nov 1997 | EP |
0479557 | Jul 1998 | EP |
0876805 | Nov 1998 | EP |
0880949 | Dec 1998 | EP |
0891751 | Jan 1999 | EP |
0895759 | Feb 1999 | EP |
0904745 | Mar 1999 | EP |
0937442 | Aug 1999 | EP |
0347023 | Dec 1999 | EP |
1031328 | Aug 2000 | EP |
1031329 | Aug 2000 | EP |
0883384 | Dec 2000 | EP |
0862392 | Aug 2001 | EP |
0808140 | Dec 2001 | EP |
0884028 | Feb 2002 | EP |
1190685 | Mar 2002 | EP |
0897700 | Jul 2002 | EP |
0684022 | Feb 2004 | EP |
1157674 | Jul 2005 | EP |
1031330 | Nov 2005 | EP |
1070513 | Jun 2006 | EP |
2678508 | Jan 1993 | FR |
2740346 | Oct 1995 | FR |
2756173 | Nov 1996 | FR |
2337002 | May 1998 | GB |
8806026 | Aug 1988 | WO |
9521592 | Aug 1995 | WO |
9629955 | Oct 1996 | WO |
9634580 | Nov 1996 | WO |
9641592 | Dec 1996 | WO |
9707752 | Mar 1997 | WO |
9715346 | May 1997 | WO |
9716217 | May 1997 | WO |
9726936 | Jul 1997 | WO |
9741803 | Nov 1997 | WO |
9745073 | Dec 1997 | WO |
9746174 | Dec 1997 | WO |
9819628 | May 1998 | WO |
9836709 | Aug 1998 | WO |
9837833 | Sep 1998 | WO |
9847447 | Oct 1998 | WO |
9848879 | Nov 1998 | WO |
9903426 | Jan 1999 | WO |
9904726 | Feb 1999 | WO |
9915103 | Apr 1999 | WO |
9915109 | Apr 1999 | WO |
9924104 | May 1999 | WO |
9934749 | Jul 1999 | WO |
9936002 | Jul 1999 | WO |
9936015 | Jul 1999 | WO |
9944539 | Sep 1999 | WO |
9956661 | Nov 1999 | WO |
9965419 | Dec 1999 | WO |
0007523 | Feb 2000 | WO |
0010489 | Mar 2000 | WO |
0016719 | Mar 2000 | WO |
0027307 | May 2000 | WO |
0027463 | May 2000 | WO |
0028922 | May 2000 | WO |
0145594 | Jun 2000 | WO |
0044307 | Aug 2000 | WO |
0044309 | Aug 2000 | WO |
0047134 | Aug 2000 | WO |
0048531 | Aug 2000 | WO |
0049951 | Aug 2000 | WO |
0051523 | Sep 2000 | WO |
0057813 | Oct 2000 | WO |
0067673 | Nov 2000 | WO |
0071054 | Nov 2000 | WO |
0071055 | Nov 2000 | WO |
0074595 | Dec 2000 | WO |
0121095 | Mar 2001 | WO |
0121109 | Mar 2001 | WO |
0121244 | Mar 2001 | WO |
0135715 | May 2001 | WO |
0135863 | May 2001 | WO |
0139697 | Jun 2001 | WO |
0139699 | Jun 2001 | WO |
0141677 | Jun 2001 | WO |
0143665 | Jun 2001 | WO |
0143809 | Jun 2001 | WO |
0145785 | Jun 2001 | WO |
0149342 | Jul 2001 | WO |
0154621 | Aug 2001 | WO |
0154622 | Aug 2001 | WO |
0158385 | Aug 2001 | WO |
0160284 | Aug 2001 | WO |
0170294 | Sep 2001 | WO |
0170299 | Sep 2001 | WO |
0174273 | Oct 2001 | WO |
0189409 | Nov 2001 | WO |
0200138 | Jan 2002 | WO |
02053066 | Jul 2002 | WO |
02068012 | Sep 2002 | WO |
03007842 | Jan 2003 | WO |
03055414 | Jul 2003 | WO |
03063924 | Aug 2003 | WO |
2004026174 | Apr 2004 | WO |
2004026180 | Apr 2004 | WO |
2005009295 | Feb 2005 | WO |
2005014077 | Feb 2005 | WO |
2006028925 | Mar 2006 | WO |
Number | Date | Country | |
---|---|---|---|
20060271159 A1 | Nov 2006 | US |